Acute Myeloid Leukemia (aml) - Pipeline Assessment And Market Forecasts To 2017

By:


GlobalData estimated the global Acute Myeloid Leukemia (AML) therapeutics market to be worth $174m in 2009. It is expected to grow to $279m with a Compound Annual Growth Rate (CAGR) of 6.1% by 2017. This growth is primarily attributed to the increase in the prevalence due to the increasing elderly population and the presence of a strong pipeline with many emerging therapies. Pfizer and Genzyme are the market leaders within the global AML therapeutics market. There is a high level of unmet need in the current AML market in terms of both safety and efficacy

The prevalence rate for AML globally was found to be 0.1% or 827,671 people. AML is a cancerous condition primarily associated with the elderly. The onset of the condition mostly occurs between the ages of 50 and 65. The yearly incidence of new AML diagnoses in the US is 17.6/100,000 for people 65 years of age or older, compared to 1.8/100,000 for people


About the Author:
GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage including oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries.



Article Originally Published On: http://www.articlesnatch.com


|

Loading...
Related....
Videos...

Recent Health Articles

Comments

Still can't find what you are looking for? Search for it!

Loading

Copyright 2005-2011 ArticleSnatch, LLC - All Rights Reserved.
Privacy Policy | Terms of Service.